Changes in enzyme activity and expression of DHFR of *Toxoplasma gondii* by antifolates

Eun-Jung BAEK and Ho-Woo NAM*

Department of Parasitology, College of Medicine, Catholic University of Korea, Seoul 137-701, Korea

Abstract: The responses to antifolates of *Toxoplasma gondii* were investigated by measuring the dihydrofolate reductase (DHFR) activity, quantity of DHFR mRNA, and single-strand conformational polymorphism (SSCP) pattern. Pyrimethamine (PYM) and methotrexate (MTX) were tested as antifolates. When *T. gondii* was treated with PYM, the viability was decreased by the increasing concentration of PYM. DHFR activity tended to increase as the passage proceeded, and the quantity of mRNA expressed was also increased according to passages. The viability of *T. gondii* was decreased by the increasing concentration of MTX, but it was maintained over 40% up to 100 μ M MTX. DHFR activity was 77.4% in the 1st passage (1 μ M), 82.2% in the 4th passage (10 μ M), and 141.3% in the 7th passage (100 μ M). But no changes were detected in SSCP pattern of *T. gondii* exposed to PYM and MTX, both. These results suggested that the response of *T. gondii* to PYM was regulated by transcriptional level and that, in MTX, the viability of *T. gondii* was derived from increasing DHFR activity.

Key words: *Toxoplasma gondii*, DHFR activity, RT-PCR, SSCP, pyrimethamine, methotrexate

INTRODUCTION

The protozoan parasite *Toxoplasma gondii* is a ubiquitous pathogen long known for its congenital infections (Remington and Desmonts, 1989). More recently, *T. gondii* has achieved considerable notoriety as an opportunistic infection afflicting AIDS patients (Luft and Remington, 1992).

Traditional treatment of toxoplasmosis involves blocking the folate metabolic pathway (Thaithong *et al.*, 1992). Dihydrofolate reduct-

ase (DHFR) and thymidylate synthase (TS) take part in the folate metabolic pathway that supplies dTMP for DNA synthesis. In protozoa, DHFR and TS are on the same polypeptide chain: the DHFR domain is on the amino terminus, the TS domain is on the carboxyl terminus (Santi and Danenberg, 1984). The bifunctional DHFR-TS appears to be optimized for continuous dTMP synthesis. Co-transcription and co-translation of the two enzymes may provide an important element of coordinate control (Ivanetich and Santi, 1990). For that reason, DHFR and TS are targets for chemotherapy, as inhibition of either enzyme disrupts the dTMP cycle and results in the thymineless death of parasites. DHFR has been successfully used as a drug target in the treatment of diseases caused by protozoa, such as malaria, *Pneumocystis carinii* pneumonia, and toxoplasmosis (Garette *et al.*,

• Received 27 June 1998, accepted after revision 21 August 1998.

• This study was supported by the research grant (No. 961-0716-101-1) from the Korean Science and Engineering Foundation (1996).

* Corresponding author (e-mail: howoo@cmc.cuk.ac.kr)

1989). But antifolate resistant strains of other protozoa are found frequently, most of which have one or two point mutations in the DHFR domain (Reeder *et al.*, 1996).

We investigated the concrete overcoming mechanism of *T. gondii* to permissive concentrations of antifolates. For studying the responses in the translational level, DHFR activity was measured in normal RH strain and *T. gondii* treated with pyrimethamine and methotrexate. For transcriptional level, the density of DHFR and P30 gene was scanned after RT-PCR amplification. Single-strand conformational polymorphism (SSCP) was also performed to detect the changes of genomic DNA.

MATERIALS AND METHODS

Maintenance of host cells and *T. gondii*

U937 cells (human neoplastic leukemia cell line, ATCC CRL 1593) were cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco BRL Co.) supplemented with 10% fetal bovine serum (FBS, Gemini Co.). *Toxoplasma gondii* (RH strain) were maintained by peritoneal passage in ICR mice.

Treatment of antifolates

Pyrimethamine (PYM, 0.001-10 μ M) and methotrexate (MTX, 0.05-100 μ M) were tested as antifolates. The growth rate was monitored by the uptake of [3 H]-uracil (Dupont, 1 mCi/ml) uptake (Pfefferkorn and Pfefferkorn, 1977) with the control without antifolates. And every 3rd passage, the concentration of antifolates was increased by 10 fold up to permissive concentration.

DHFR activity

Protein concentration of the crude extract of PYM and MTX treated RH was measured by the Bradford method using BSA as a standard (Bradford, 1976). DHFR activity was determined spectrophotometrically by monitoring the decrease in the absorbance at 340 nm, 25°C in a reaction mixture containing Tris-HCl (50 mM, pH 7.6), β -mercaptoethanol (100 mM), KCl (150 mM), NADPH (100 μ M), DHF (100 μ M) and EDTA (1 mM). The reaction was initiated by addition of DHF (Hillcoat *et al.*,

1969). The decrease in A340 was monitored by spectrophotometer (8450A UV/VIS, Hewlett Packard Co.). The specific activity of the enzyme was calculated as $\text{mg}^{-1}\text{min}^{-1}$. The specific activity of normal RH was calculated at 100%.

Quantitation of DHFR mRNA by RT-PCR

DHFR mRNA was separated by Oligotex Direct mRNA micro kit (Qiagen 72012) to synthesize cDNA by reverse transcriptase (1st strand cDNA synthesis kit, Boehringer Mannheim). DHFR gene was amplified using the primers designed according to the sequence of Roos (1993), using upstream primer: 5'-CCATCGATATGCAGAAACCGGTGTGTCT-3' and downstream primer: 5'-CCATC GATACAAAGTCGTAGGGTACCCC-3'. To calculate the expression ratio, the major surface protein (P30) fragments of *T. gondii* was amplified with the same substrate using upstream primer: 5'-GCTCTAGATCACGC GACACAAGCTGC-3' and downstream primer: 5'-GCTCTAGATGTCTCGGTTTCGCTGCAC-3' (Nam *et al.*, 1996) with restricted cycles in a programmable thermal controller (PTC-100, MJ Research Inc.). PCR product was electrophoresed on a 1.5% agarose gel at 70 mA for 40 min. The density of DHFR gene and P30 gene was measured by a video system (Eagle Eye II, Stratagene Co.), then the ratio of DHFR/P30 was calculated (Wang *et al.*, 1989).

Detection of mutation in DHFR gene

Genomic DNA was obtained to use as substrate for PCR (Sambrook *et al.*, 1989). The reactions were amplified as follows: initial denaturation for 30 sec at 95°C and 29 cycles with denaturation at 95°C for 1 min, annealing at 56°C for 1 min, and extension at 72°C for 2 min. The entire 1.73 kb of *T. gondii* DHFR gene was amplified using the same primers described above. After confirmed in 1.5% agarose gels, each PCR product was used as substrate for the 2nd PCR by the primer sets in Table 1 for optimum separation in SSCP. During the reaction, ^{35}S -dATP was incorporated, and PCR products were separated on 6% acrylamide gel under 500-800 V (30 mA) for 3-4 hrs. The gel was exposed to X-ray film to detect mutation (Dean and Gerrard, 1991).

Table 1. Primer sets to amplify the exon parts of DHFR genomic DNA of *T. gondii*

Name	Sequence of primers	Amplified DNA
B1 sense	5'-ATGCAGAAACCGGTGTGT-3'	— anterior of exon I, 180 bp
B2 antisense	5'-CGTCTTTGCAAATTCCT-3'	
B3 sense	5'-CCCGAAGAAGCCATGCGC-3'	— posterior of exon I, 189 bp
B4 antisense	5'-GGAAGAGGAAACGACGAT-3'	
B5 sense	5'-AAAGAAGAAGACATTGCG-3'	— exon II, 135 bp
B6 antisense	5'-CACGACAAAAATCTGGTC-3'	
B7 sense	5'-GGAGCGGGACTGTACGAG-3'	— anterior of exon III, 180 bp
B8 antisense	5'-GGGAACGAACACAGACTC-3'	
B9 sense	5'-GCAGCTCCTGCCGAGTCT-3'	— posterior of exon III, 180 bp
B10 antisense	5'-CCATCGATACAAAGTCGTAGGGTACCCC-3'

Fig. 1. Growth of *T. gondii* treated with various concentrations of PYM (A) and MTX (B). [^3H]-uracil uptake was counted and calculated as % to normal RH.

Plasmodial DHFR mutant gene M2M3 (Ser36 → Arg, Thr83 → Asn) was used as a positive control (Robert *et al.*, 1993).

RESULTS

Both antifolates inhibited the growth of *T. gondii* with a little different pattern. When *T. gondii* was treated with PYM from 0.001 μM to 10 μM , the [^3H]-uracil uptake ratio to control was decreased as the PYM concentration was increased (Fig. 1A). At the concentration less than 0.05 μM , the ratio was decreased rapidly by 74.4% from 97.7% at 0.001 μM to 23.3% at 0.05 μM . At more than 5 μM PYM, the ratio

was decreased slowly, but maintained in 10%. When treated with MTX, the ratio was decreased slowly, but maintained over 40% from 5 μM to 100 μM MTX (Fig. 1B). It was estimated that the permissive concentration of PYM was up to 0.1 μM for the passage of *T. gondii*. And in case of MTX, concentration up to 100 μM was permissive for the passage.

DHFR activity with uracil uptake to control by the passage was described in Fig. 2. That of normal RH was 0.23 $\text{mg}^{-1}\text{min}^{-1}$ (100%). At 0.01 μM PYM, DHFR activity ratio to control was 33.9% in the 1st passage, 47.0% in the 2nd passage, and 47.4% in the 3rd passage. After increasing the PYM concentration to 0.1 μM ,

Fig. 2. DHFR activity and uracil uptake of *T. gondii* with PYM (A) and MTX (B). A: passage 1, 2, and 3 were treated with 0.01 μM PYM and passage 4 with 0.1 μM . B: passage 1, 1 μM MTX; passage 4, 10 μM ; and passage 7, 100 μM .

DHFR activity was recovered to 63.5% in the 4th passage (Fig. 2A). During the passage, the profile of uracil uptake ratio was followed to the DHFR activity except the 2nd passage that increased to 135.2%. In the passage under MTX treatment, the enzyme activity was increased slowly from 77.4% in the 1st passage with 1 μM MTX, 82.2% in the 4th passage with 10 μM , and to 141.3% in the 7th passage with 100 μM (Fig. 2B). Uracil uptake showed a similar pattern with DHFR activity.

The ratio of DHFR/P30 mRNA expressed was obtained indirectly by RT-PCR of each mRNA. In normal RH, the ratio of DHFR/P30 mRNA expression was 0.64 under condition used. There were quantitative changes of DHFR mRNA from the 1st passage to the 4th passage with PYM. The ratio of DHFR/P30 was decreased by 0.5, 0.51, 0.49, and 0.53 in 0.001 μM , 0.005 μM , 0.01 μM , and 0.05 μM PYM in the 1st passage, respectively. That of DHFR/P30 was increased by 0.78, 1.29, 1.95, and 2.92 in the 4th passage of which the concentration of PYM was increased 10 fold to 0.01 μM (P1), 0.05 μM (P2), 0.1 μM (P3), and 0.5 μM (P4) (Fig. 3A). The ratio of DHFR/P30 was 1.14, 1.45, 2.20, and 0.75 in 0.05 μM , 0.5 μM , 5 μM , and 50 μM MTX in the 1st passage, but changed irregularly as 0.7, 2.57, 1.10 and 0.31 after increasing the concentration to 0.5

μM (M1), 5 μM (M2), 50 μM (M3), and 100 μM (M4), respectively (Fig. 3B).

In SSCP pattern of DHFR exon fragments of *T. gondii* exposed to PYM and MTX showed no differences comparing to that of normal RH. This indicated that there were no changes of DHFR gene in the genomic level when exposed to both PYM and MTX (Fig. 4A & B).

DISCUSSION

Both PYM and MTX induced different overcoming responses in *T. gondii* such as changes in DHFR activity and expression of DHFR mRNA. By PYM, *T. gondii* regulated the expression of DHFR mRNA to overcome the drug. And the over-expression of mRNA was dose dependent as shown in Fig. 3. After shifting to 10-fold from various concentrations of PYM as in P1, P2, P3 and P4, the quantity of mRNA was increased to 1.56, 2.47, 4.00 and 5.54 folds, respectively. But in case of MTX treatment, *T. gondii* regulated the DHFR activity rather than expression of DHFR mRNA, although the pattern of the latter was not defined clearly. DHFR activity was decreased by 77.4% in the 1st passage (1 μM), after then increased by 141.7% in the 7th passage (100 μM). Totally the responses were in the boundary of protein level and trans-

Although MTX is one of strong DHFR inhibitors, it was difficult to induce the changes in genomic level with these concentrations except by increasing DHFR activity in this study. In *T. gondii*, although it was not the same pattern, the reaction to PYM and MTX was similar to that of *Leishmania major*. MTX was much less effective in culture against *T. gondii* than its potency *in vitro* suggested it might be (Mack and Mcleod, 1984).

with a lethal dose of an antifolate that is an analogue of DHF or DHFR inhibitor, the parasites are dealt a fatal blow. If the concentration of antifolates is less than lethal dose, they change their survival strategies according to those conditions. They inhibit uptake of drugs, and quickly expell drugs from cells, or increase the quantity of enzyme, and induce conformational changes of structure of enzyme to inhibit the binding of antifolates (Wellem, 1991). In *L. major*, resistant-antifolate was derived from DHFR gene amplification. Antifolate resistant strains of *L. major* amplify the DHFR-TS gene in extrachromosomal circular DNAs which is correlated with enzyme overproduction, R region (Beverly, 1991). It

Fig. 4. SSCP pattern of DHFR exon fragments of *T. gondii* treated with PYM (A) and MTX (B). B1/B2 and B3/B4 : primer sets in Table 1 (DNA fragments from other primer sets not shown). A: 1, normal RH; 2, M2M3 (positive control); 3, P1 (0.001 μ M PYM); 4, P2 (0.005 μ M); 5, P3 (0.1 μ M); and 6, P4 (0.05 μ M). B: 1, M2M3; 2, normal RH; 3, passage 1; 4, passage 2; 5, passage 3 (1 μ M MTX); 6, passage 4 (10 μ M); and 7, passage 7 (100 μ M).

appears that drug resistance in parasitic protozoa may be mediated by gene amplification (Coderre *et al.*, 1983). Foote (1990) reported that amino acids involved in cycloguanil resistance differed from those involved in PYM resistance. Others have recently developed transformation systems capable of both transient and stable expression of recombinant transgenes in *T. gondii* (Soldati and Boothroyd, 1993). Selection with PYM permits the isolation of stable clones harboring the mutant DHFR-TS gene at high frequency. Depending on the particular drug resistance allele chosen and conditions of selection, it is possible to select for the amplified transgenes or single copy chromosomal insertions (Peterson *et al.*, 1988).

In PYM-resistant strains of *Plasmodium falciparum*, all have a common point mutation in the DHFR coding sequence which causes decreased binding of the folate analogue (Zol-

et al., 1989). Resistant *P. falciparum* possessed mutation in the DHFR gene at codon 108, the majority changing from Ser/Thr to Asn, Cys59 to Arg, and Phe223 to Ser (Reeder *et al.*, 1996). Point mutation and gene amplification gave an important resistance mechanism to parasites. Isolated drug-resistant strains have been believed to be induced by continuous chemotherapy until now. But, with these results, the stability of DHFR gene was very strong to drug exposure, even though the DNA contents are in asexual stage (1N) that is expected to be much higher possibility of mutation. It was suggested that the mutated isolations might be caused by adaptation to drug resistance after random spontaneous mutation to any other environmental factors in addition to continuous exposure to drug only.

REFERENCES

- Beverley SM (1991) Gene amplification in *Leishmania*. *Ann Rev Microbiol* **45**: 417-444.
- Bradford MM (1976) A rapid and sensitive method for the principle for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72**: 248-254.
- Coderre JA, Beverley SM, Shimke RT, Santi DV (1983) Overproduction of a bifunctional thymidylate synthase-dihydrofolate reductase and DNA amplification in methotrexate-resistant *Leishmania tropica*. *PNAS USA* **80**: 2132-2136.
- Dean M, Gerrard B (1991) Helpful hints for the detection of single-stranded conformation polymorphism. *Biotechniques* **10**: 332-333.
- Foote S, Galatis D, Cowman AF (1990) Amino acids in the dihydrofolate reductase-thymidylate synthase gene of *Plasmodium falciparum* involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. *PNAS USA* **87**: 3014-3017.
- Garrette CE, Coderre JA, Meek TD, *et al.* (1984) A bifunctional thymidylate synthase-dihydrofolate reductase of protozoa. *Mol Biochem Parasitol* **11**: 257-265.
- Hillcoat BL, Nixon PF, Blakley RL (1967) Effect of substrate decomposition on the spectrophotometric assay of dihydrofolate reductase. *Anal Biochem* **21**: 178-189.
- Ivanetich KM, Santi DV (1990) Thymidylate

- synthase-dihydrofolate reductase in protozoa. *Exp Parasitol* **70**: 367-371.
- Luft BJ, Remington JS (1992) Toxoplasmic encephalitis in AIDS. *Clin Infect Dis* **15**: 211-212.
- Mack DG, McLeod R (1984) New micromethod to study the effect of antimicrobial agents on *Toxoplasma gondii*: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. *Antimicrob Agents Chemoth* **26**: 26-30.
- Nam HW, Im KS, Baek EJ, Choi WY, Cho SY (1996) Analysis of antigenic domain of GST fused major surface protein (P30) fragments of *Toxoplasma gondii*. *Korean J Parasitol* **34**(2): 135-141.
- Peterson DS, Walliker D, Wellems TE (1988) Evidence that a point mutation in dihydrofolate reductase thymidylate synthase confers resistance to pyrimethamine in *Plasmodium falciparum* malaria. *PNAS USA* **85**: 9114-9118.
- Pfefferkorn ER, Pfefferkorn LC (1977) Specific labeling of intracellular *Toxoplasma gondii* with uracil. *J Protozool* **24**(3): 449-453.
- Reeder JC, Riedeckmann KH, Lorry K, Wines B, Cowman AF (1996) Point mutations in dihydrofolate reductase and dihydropteroate synthase genes and *in vitro* susceptibility to pyrimethamine and cycloguanil of *Plasmodium falciparum* isolates from Papua New Guinea. *Am J Trop Med Hyg* **55**(2): 209-213.
- Remington JS, Desmonts G (1989) Congenital toxoplasmosis. In *Infectious diseases in fetus and newborn infant*, Remington JS and Klein JO (ed.). p89-195, W.B. Saunders, Philadelphia, USA.
- Robert G, Donald K, Roos DS (1993) Stable molecular transformation of *Toxoplasma gondii*: A selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria. *PNAS USA* **90**: 11703-11707.
- Roos DS (1993) Primary structure of the dihydrofolate reductase-thymidylate synthase gene from *Toxoplasma gondii*. *J Biol Chem* **268**: 6269-6280.
- Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: A laboratory manual, 2nd eds., Cold Spring Harbor Laboratory Press, CSH, New York, USA.
- Santi DV, Danenberg PV (1984) Folates in pyrimidine nucleotide biosynthesis. In *Folates and Pteridines*, Blakey RL and Benkovic SJ (ed.) **1**: 343-396.
- Soldati D, Boothroyd JC (1993) Transient transfection and expression in the obligate intracellular parasite *Toxoplasma gondii*. *Science* **260**: 349-352.
- Thaithong S, Chan SW, Songsomboon S, et al. (1992) Pyrimethamine resistant mutations in *Plasmodium falciparum*. *Mol Biochem Parasitol* **52**: 149-158.
- Wang AM, Doyle MV, Mark DF (1989) Quantitation of mRNA by the polymerase chain reaction. *PNAS USA* **86**: 9717-9721.
- Wellems TE (1991) Molecular genetics of drug resistance in *Plasmodium falciparum* malaria. *Parasitol Today* **7**: 110-112.
- Zolg JW, Plitt JR, Chen GX, Palmer S (1989) Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in *Plasmodium falciparum*. *Mol Biochem Parasitol* **36**: 253-262.

=초록=

Antifolate 약제에 대한 독소포자충의 DHFR 효소활성 및 유전자 발현의 변화

백은정, 남호우

가톨릭대학교 의과대학 기생충학교실

독소포자충의 pyrimethamine (PYM)과 methotrexate (MTX)에 대한 효소활성 및 유전자 발현의 변화를 살펴본 결과 두 약제를 처리한 경우 모두 약제 농도의 증가에 따라 생존력이 감소하였으며, 계대가 진행됨에 따라 DHFR 효소활성은 증가하였다. PYM의 경우, 0.01 μM 을 사용한 1차 계대시 효소 활성이 33.9%를 나타낸 반면, 10배로 농도를 증가시킨 4차 계대에서는 63.5%로 약 2배 증가하였다. MTX의 경우에는 1차 계대시 77.4% (1 μM), 4차 계대시 82.2% (10 μM), 7차 계대시에는 141.3% (100 μM)로 1차 계대와 비교하여 볼 때 효소활성이 약 183% 증가한 것으로 나타났다. 특히 DHFR mRNA의 양은 4차 계대시에 1차 계대시와 비교하였을 때, PYM 농도 증가에 따라 각각 1.5배 이상씩 증가하였으며, MTX의 경우 역시 mRNA 양의 변화는 관찰되었으나, 그 변화에 따른 유의성은 없었다. 이상의 결과로 PYM에 대한 독소포자충의 반응은 DHFR 효소활성 증가 및 mRNA 수준 즉, transcriptional level에서 조절되는 것임을 알 수 있었으며, MTX에 대한 독소포자충의 반응은 DHFR 효소활성 증가에 기인하나, PYM에 의해 유발되는 반응과는 다른 약제 극복 기전이 존재하는 것으로 추정되었다.

[기생충학잡지 36(3): 191-198, 1998년 9월]